In @ patients receiving gemcitabine at any time during study treatment ( either within the @st - or @nd-line setting ) hENT@ ( low ) cases had a median overall survival of @ months and hENT@ ( high ) patients an overall survival of @ months ( HR @ , @ % CI @-@ @ , p = @ ) , respectively .